Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Federal Trade Commission
Accenture
Dow
Covington
Daiichi Sankyo
Teva
Citi
McKinsey

Generated: April 22, 2018

DrugPatentWatch Database Preview

FLOLAN Drug Profile

« Back to Dashboard

When do Flolan patents expire, and what generic alternatives are available?

Flolan is a drug marketed by Glaxosmithkline Llc and is included in one NDA.

The generic ingredient in FLOLAN is epoprostenol sodium. There are seven drug master file entries for this compound. Three suppliers are listed for this compound. Additional details are available on the epoprostenol sodium profile page.
Drug patent expirations by year for FLOLAN
Pharmacology for FLOLAN
Ingredient-typeProstaglandins I
Drug ClassProstacycline Vasodilator
Physiological EffectVasodilation
Medical Subject Heading (MeSH) Categories for FLOLAN
Synonyms for FLOLAN
(5E)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3R)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z,13E,15S)-6,9alpha-epoxy-11alpha,15-dihydroxyprosta-5,13-dienoic acid
(5Z,13E)-(15S)-6,9alpha-Epoxy-11alpha,15-dihydroxyprosta-5,13-dienoate
(5Z,9alpha,11alpha,13E,15S)-11,15-dihydroxy-6,9-epoxyprosta-5,13-dien-1-oic acid
(5Z,9alpha,11alpha,13E,15S)-6,9-epoxy-11,15-dihydroxyprosta-5,13-dien-1-oic acid
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(5Z)-5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[d]furan-2-ylidene]pentanoic acid
(5Z)-5-[(4R,5R)-5-hydroxy-4-[(E,3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
(Z)-(3aR,4R,5R,6aS)-Hexahydro-5-hydroxy-4-((E)-(3S)-3-hydroxy-1-octenyl)-2H-cyclopenta(b)furan-delta(sup 2,delta)-valeric acid
(Z)-5-((3aR,4R,5R,6aS)-5-hydroxy-4-((S,E)-3-hydroxyoct-1-en-1-yl)hexahydro-2H-cyclopenta[b]furan-2-ylidene)pentanoic acid
35121-78-9
5-[(3aR,4R,5R,6aS)-5-hydroxy-4-[(3S)-3-hydroxyoct-1-enyl]-3,3a,4,5,6,6a-hexahydrocyclopenta[b]furan-2-ylidene]pentanoic acid
54231-EP2305653A1
54231-EP2308562A2
6,9-alpha-Epoxy-11-alpha,15(S)-dihydroxyprosta-5(Z),13(E)-dien-1-oic acid
6,9.alpha.-Epoxy-11.alpha.,15S-dihydroxyprosta-5Z,13E-dien-1-oic acid, monosodium salt
6,9S-epoxy-11R,15S-dihydoxy-5Z,13E-prostadienoic acid
63748-50-5
63859-31-4
8222AH
88471-EP2272832A1
88471-EP2289518A1
88471-EP2292231A1
88471-EP2305260A1
88471-EP2305653A1
AC1NR00P
BIDD:GT0514
BRD-K64054020-001-02-7
BRN 1690090
BSPBio_001496
CHEBI:15552
CHEMBL1139
D0V0IX
DCR9Z582X0
DTXSID5022988
Epoprostanol
epoprostenol
Epoprostenol (USAN/INN)
Epoprostenol [USAN:INN]
Epoprostenol sodium
Epoprostenolum
Epoprostenolum [INN-Latin]
GTPL1915
HMS1791K18
HMS1989K18
HMS3402K18
IDI1_033966
KAQKFAOMNZTLHT-OZUDYXHBSA-N
KB-IV-24
LMFA03010087
NCGC00161285-01
NCGC00161285-02
NCGC00161285-03
PG-I2
PGI(sub 2)
PGI2
PGX
Prosta-5,13-dien-1-oic acid, 6,9-epoxy-11,15-dihydroxy-, (5Z,9alpha,11alpha,13E,15S)-
prostacyclin
Prostacyclin I2
Prostacycline
Prostacyclins
Prostaglandin 12
Prostaglandin I(2)
prostaglandin I2
Prostaglandin X
ProstaglandinI
Prostaglandins X
SCHEMBL8041
SMP2_000227
TRY 200
Try-200
U 53,217
U-53,217
U-53217
UNII-DCR9Z582X0
Vasocyclin
ZINC3813078

US Patents and Regulatory Information for FLOLAN

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-001 Sep 20, 1995 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-002 Sep 20, 1995 AP RX Yes Yes ➤ Sign Up ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Expired US Patents for FLOLAN

Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-001 Sep 20, 1995 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-001 Sep 20, 1995 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-002 Sep 20, 1995 ➤ Sign Up ➤ Sign Up
Glaxosmithkline Llc FLOLAN epoprostenol sodium INJECTABLE;INJECTION 020444-001 Sep 20, 1995 ➤ Sign Up ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date Patent No. Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Covington
QuintilesIMS
Chinese Patent Office
Merck
Daiichi Sankyo
Cantor Fitzgerald
Citi
Harvard Business School
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.